The development of a mouse model of post-bariatric hyperinsulinemic hypoglycemia

BACKGROUND: Post-bariatric hypoglycemia (PBH), a complication of gastric bypass surgery, is characterized by postprandial hyperinsulinemic hypoglycemia. To date, the etiology of PBH has not been fully elucidated. OBJECTIVE: To develop a murine model of PBH by experimentally modifying candidate mole...

Full description

Bibliographic Details
Main Author: Smith, Catherine Mary
Language:en_US
Published: 2017
Subjects:
Online Access:https://hdl.handle.net/2144/23731
id ndltd-bu.edu-oai-open.bu.edu-2144-23731
record_format oai_dc
spelling ndltd-bu.edu-oai-open.bu.edu-2144-237312019-03-18T15:24:01Z The development of a mouse model of post-bariatric hyperinsulinemic hypoglycemia Smith, Catherine Mary Endocrinology Diabetes Endocrinology Hypoglycemia Bariatric surgery Post bariatric hypoglycemia BACKGROUND: Post-bariatric hypoglycemia (PBH), a complication of gastric bypass surgery, is characterized by postprandial hyperinsulinemic hypoglycemia. To date, the etiology of PBH has not been fully elucidated. OBJECTIVE: To develop a murine model of PBH by experimentally modifying candidate molecules identified in humans with PBH. METHODS: Gastric bypass patients were assigned to groups based on whether or not they suffered from hypoglycemia (PBH, n = 11; asymptomatic, n = 7). Patients underwent a mixed meal tolerance test with blood draws at baseline, 30 minutes, and 120 minutes postprandially. SOMAscan (Somalogic) was used to evaluate serum for protein levels. In parallel, mass spectrometry (Metabolon) was used to examine metabolite levels. Mice were treated with the Farnesoid X Receptor (FXR) agonist, fexaramine (Fex), or vehicle for 5 days before undergoing a glucose tolerance test (GTT). Mice were sacrificed with tissues collected immediately thereafter. PCR was performed to quantify expression of FXR target genes. A separate cohort of mice was treated with adenine or vehicle for 2 days before undergoing a GTT or an insulin tolerance test. RESULTS: FGF19 was the most significantly upregulated protein in the PBH group at all time points. At 120 minutes postprandially, FGF19 was 2.1-fold higher in the PBH group (p < 1x10-5). Adenine was >2-fold higher at all time points (p < 1x10-8). Treatment with Fex did not result in significant differences during GTT or in expression of FXR target genes. Treatment with adenine did not significantly impact glucose tolerance or insulin sensitivity between groups. CONCLUSIONS: The results of the human serum analyses established a strong foundation on which to develop a murine model of PBH. Though the mouse experiments failed to induce postprandial hypoglycemia, they have directed future experiments toward developing a murine model of PBH. 2018-07-11T00:00:00Z 2017-09-07T14:20:15Z 2017 2017-07-12T01:11:29Z Thesis/Dissertation https://hdl.handle.net/2144/23731 en_US
collection NDLTD
language en_US
sources NDLTD
topic Endocrinology
Diabetes
Endocrinology
Hypoglycemia
Bariatric surgery
Post bariatric hypoglycemia
spellingShingle Endocrinology
Diabetes
Endocrinology
Hypoglycemia
Bariatric surgery
Post bariatric hypoglycemia
Smith, Catherine Mary
The development of a mouse model of post-bariatric hyperinsulinemic hypoglycemia
description BACKGROUND: Post-bariatric hypoglycemia (PBH), a complication of gastric bypass surgery, is characterized by postprandial hyperinsulinemic hypoglycemia. To date, the etiology of PBH has not been fully elucidated. OBJECTIVE: To develop a murine model of PBH by experimentally modifying candidate molecules identified in humans with PBH. METHODS: Gastric bypass patients were assigned to groups based on whether or not they suffered from hypoglycemia (PBH, n = 11; asymptomatic, n = 7). Patients underwent a mixed meal tolerance test with blood draws at baseline, 30 minutes, and 120 minutes postprandially. SOMAscan (Somalogic) was used to evaluate serum for protein levels. In parallel, mass spectrometry (Metabolon) was used to examine metabolite levels. Mice were treated with the Farnesoid X Receptor (FXR) agonist, fexaramine (Fex), or vehicle for 5 days before undergoing a glucose tolerance test (GTT). Mice were sacrificed with tissues collected immediately thereafter. PCR was performed to quantify expression of FXR target genes. A separate cohort of mice was treated with adenine or vehicle for 2 days before undergoing a GTT or an insulin tolerance test. RESULTS: FGF19 was the most significantly upregulated protein in the PBH group at all time points. At 120 minutes postprandially, FGF19 was 2.1-fold higher in the PBH group (p < 1x10-5). Adenine was >2-fold higher at all time points (p < 1x10-8). Treatment with Fex did not result in significant differences during GTT or in expression of FXR target genes. Treatment with adenine did not significantly impact glucose tolerance or insulin sensitivity between groups. CONCLUSIONS: The results of the human serum analyses established a strong foundation on which to develop a murine model of PBH. Though the mouse experiments failed to induce postprandial hypoglycemia, they have directed future experiments toward developing a murine model of PBH. === 2018-07-11T00:00:00Z
author Smith, Catherine Mary
author_facet Smith, Catherine Mary
author_sort Smith, Catherine Mary
title The development of a mouse model of post-bariatric hyperinsulinemic hypoglycemia
title_short The development of a mouse model of post-bariatric hyperinsulinemic hypoglycemia
title_full The development of a mouse model of post-bariatric hyperinsulinemic hypoglycemia
title_fullStr The development of a mouse model of post-bariatric hyperinsulinemic hypoglycemia
title_full_unstemmed The development of a mouse model of post-bariatric hyperinsulinemic hypoglycemia
title_sort development of a mouse model of post-bariatric hyperinsulinemic hypoglycemia
publishDate 2017
url https://hdl.handle.net/2144/23731
work_keys_str_mv AT smithcatherinemary thedevelopmentofamousemodelofpostbariatrichyperinsulinemichypoglycemia
AT smithcatherinemary developmentofamousemodelofpostbariatrichyperinsulinemichypoglycemia
_version_ 1719003963134574592